ICON Named Business & Finance Company of the Year and One of Forbes’ Best Employers for Diversity
23 Maio 2022 - 8:00AM
Business Wire
ICON kick starts the first half of 2022 with a
string of prestigious industry awards recognising healthcare
intelligence work and staff, as independently judged by peers
worldwide
ICON plc, (NASDAQ: ICLR) a global provider of drug and device
development and commercialisation services to pharmaceutical,
biotechnology, medical device, and government organisations, has
been recognised with a number of prestigious business and industry
awards in April 2022, including Company of the Year at the 2021
Business & Finance Irish Business Awards and Pharma Contract
Services Company of the Year at the Pharma Industry Awards
2021.
This is the second time the healthcare intelligence company has
received the prestigious Company of the Year accolade from the
Business and Finance Awards Programme, having previously won in
2016. Winners are chosen by an independent panel of industry
professional judges, who review market position, operational and
financial achievements, company culture and Environmental, Social
and Governance (ESG) factors.
Having already been announced as one of America’s Best Large
Employers in 2022 by Forbes, ICON has also been recognised as one
of America’s Best Employers for Diversity for the second year
running. Inclusion is one of the core values at ICON, and has been
a considerable focus for the company as part of its overall ESG
strategy. In addition to building key community groups across the
business, over the last year dedicated diversity training has been
rolled out to people leaders to support them in creating a sense of
connection and belonging within their teams.
Commenting on the company’s recent success, Steve Cutler, CEO,
ICON plc said: “To be the recipient of these awards is
exceptionally gratifying as we grow and evolve our business to be
the healthcare intelligence partner of choice. A number of
important areas of focus are reflected in these successes - our
commitment to supporting our clients and improving patients’ lives;
being an employer of choice and providing opportunity to all of our
people; and the way in which we operate alongside our focus on
developing new and innovative solutions to what we do and how we do
it. Most significantly, these awards really reflect the exceptional
talent that we have here at ICON, right across our business.”
Additional industry awards and recognition
In April, ICON won two Stevie® Awards in The 20th Annual
American Business Awards®. It received a Silver award in the Cloud
Application/Service category for ARCADES, its next generation data
integration tool, and a Bronze award in the Business or Competitive
Intelligence Solution category for IcoNex, which enables greater
connection between key opinion leaders working in the same
therapeutic area. More than 230 professionals worldwide
participated in the judging process to select this year’s Stevie
Award winners.
Further success for ICON came in the 2022 CRO Leadership Awards,
where it was recognised in the Compatibility (Big Pharma) category.
Winning CROs are chosen through impartial market research based on
feedback from sponsor companies that utilise their outsourcing
services.
Barry Balfe, President, ICON Pharma Solutions commented: “Being
a partner of choice for our clients means that we collaborate with
them and deliver insight, we are responsive to their needs and we
deliver efficiently and on time. This compatibility award is
recognition that our clients not only find us easy to work with,
but that we also support them in achieving their desired outcomes.
This is hugely positive feedback for our teams here at ICON.”
The strength of ICON’s leaders has also been recognised. In
March, Dr Nuala Murphy, President of Development and
Commercialisation Solutions, was announced as the 2021 Chambers
Ireland InBusiness Businesswoman of the Year. Nuala’s team is
focused on delivering integrated solutions that enable clients to
expedite the development of drugs and devices and to drive the
adoption of decentralised trials. She also leads the company’s
approaches to increase patient participation and diversity in
clinical trials. Nuala led the team that delivered the pivotal
phase 3 Pfizer and BioNTech COVID-19 vaccine clinical trials.
“I am honoured to receive this award. It is an acknowledgement
of what we, as a team, have been able to achieve in pioneering new
approaches to clinical research that are more efficient and
effective, and that ultimately drive better solutions for our
clients and better outcomes for patients. To be part of cutting
edge, clinical research is hugely rewarding. I’m proud of what our
teams at ICON have been able to do to drive transformation in our
industry.”
A full list of ICON’s industry awards can be viewed at
www.iconplc.com/awards.
Ends
About ICON plc
ICON is a world-leading healthcare intelligence and clinical
research organisation. From molecule to medicine, we advance
clinical research providing outsourced development and
commercialisation services to pharmaceutical, biotechnology,
medical device and government and public health organisations. We
develop new innovations, drive emerging therapies forward and
improve patient lives. With headquarters in Dublin, Ireland, ICON
employed approximately 39,300 employees in 138 locations in 53
countries as at March 31, 2022. For further information about ICON,
visit: www.iconplc.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220523005046/en/
Media: Claire Quinn (GMT time zone) Corporate
Communications, ICON plc claire.quinn@iconplc.com +353 87 4066091
Weber Shandwick (PR adviser) Lisa Henry (GMT time zone) +447785
458203 lhenry@webershandwick.com
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024